博碩士論文 105826601 詳細資訊




以作者查詢圖書館館藏 以作者查詢臺灣博碩士 以作者查詢全國書目 勘誤回報 、線上人數:21 、訪客IP:52.6.70.202
姓名 呂天蒙(Tian-Meng Lyu)  查詢紙本館藏   畢業系所 系統生物與生物資訊研究所
論文名稱 藉由L1000?表達圖譜數據來解釋中醫分類方法中的屬性和歸經
(The Attribution and Meridian of Traditional Chinese Medicine (TCM) Classification Method Explained by Analyzing L1000? Expression Profiling Data)
相關論文
★ 中草藥BP004誘導管腔A型乳腺癌細胞凋亡★ 藉由微陣列基因晶片以探討中草藥BP011w對於抑制肺腺癌細胞株爬行及轉移之機制
★ 鑑別可應用在病理與臨床之肺腺癌與鱗狀上皮細胞肺癌的生物標記★ 中國傳統醫藥蒙古黃耆在HCT116結腸癌細胞體外和體內實驗呈現腫瘤抑制作用
★ 泰莫西芬與BP012W乙醇分離物之協同作用造成強化管狀A型乳腺癌細胞凋亡影響★ 揭示CEP55基因在大腸直腸癌轉移中所扮演的角色
★ BP016W-新型食道鱗狀上皮細胞癌候選藥物★ BP023W在頭頸癌中的細胞毒性與調控機制
檔案 [Endnote RIS 格式]    [Bibtex 格式]    [相關文章]   [文章引用]   [完整記錄]   [館藏目錄]   至系統瀏覽論文 (2023-8-15以後開放)
摘要(中) 中國傳統中醫中藥一直被西方現代科學低估,但隨?從各種中藥中提取出的不同化合物用於治療疾病有?不錯的功效,所以近年來中醫藥引起了醫學領域越來越多的關注。根據中國古代的醫學文獻,中醫藥被歸為三種歸屬:寒,溫和熱藥物;中醫藥同時也被歸經分類,歸經意味著該藥的歸屬於它所影響的經脈。在本研究中,我們試圖通過分析基於中醫藥治療的癌細胞的L1000表達譜數據來解釋中醫藥的藥性與經絡之間的關係。在分析這些數據後,我們發現在各個屬性,味道和歸經的藥物處理後的細胞表現量數據差異的功能性分析來看,其不同群組之間有?不盡相同的功能。此外我們了解到,在一些特定屬性藥物的導致細胞的作用途徑可能影響癌症的發展,根據這個結果,我們選擇其中四種中藥符合我們感興趣的屬性和經絡並且通過細胞生物學實驗證明了其中三種藥物可以抑制乳癌細胞MCF7生長。最後,我們認為我們對L1000概況數據解釋的中醫藥歸因研究結果可能對中醫藥的發展有用。
摘要(英) Chinese traditional Chinese medicine has been underestimated by Western modern science, but with the different compounds extracted from various Chinese medicines used to treat diseases which have good effects, therefore, in recent years, Chinese medicine has attracted more and more attention in the medical field. According to ancient Chinese medical literature, Chinese drug are classified into three attribution: cold, medium and heat medicine; Chinese medicine is also classified as Meridian which means that the drug belongs to the meridians it affects. In this study, we attempted to explain the differences between the attribution and meridian of traditional Chinese medicine by analyzing the L1000 expression profile data of cancer cells treated with Chinese drug. After data analysis, we found that functional analysis of differences between various attributes, tastes, and meridian showed different functions between different groups. In addition, we have learned that the pathways leading to the action of cells in some specific properties may affect the development of cancer. Based on this result, we selected four TCMs which mix the attributes and meridians of our interest and we proved three of these drug’s ability of inhibiting MCF7 breast cancer cells through cell biology experiments. Finally, we believe that the results of Chinese medicine classification method studies that explain by the L1000 profile data may be useful for the development of Chinese medicine.
關鍵字(中) ★ 中藥的性味歸經
★ 藥物高通量篩選
★ 生物資訊
★ 抗癌藥物
關鍵字(英) ★ TCM classification method
★ High-throughput screening of drugs
★ Bioinformatics
★ Anticancer drugs
論文目次 中文摘要 i
Abstract ii
誌謝 iii
Table of contents iv
List of tables vi
List of figures viii
List of supplements tables ix
List of supplements figures x
1. Introduction 1
1-1. TCM classification method 1
1-2. High-throughput screening technology and L1000? Expression Profiling 4
2. Materials and methods 7
2-1. L1000? Expression Profiling Data source 7
2-2 Gene-Spring GX differential gene analysis 8
2-3. Function and pathway analysis 8
2-4. Cell line 9
2-5. Drug preparation 9
2-6. Cell viability measurement 9
3. Results 11
3-1.1 L1000? Expression Profiling Data organization 11
3-1.2. Differential gene functional analysis correlated with TCM attribution classification 16
3-1.3. Differential gene functional analysis correlated with TCM taste classification 19
3-1.4. Differential gene functional analysis correlated with TCM Meridian attribution classification 22
3-2.1. Differential gene functional analysis divided from TCM Meridian and attribution classification focus on specific term research 26
3-2.2. In vitro cytotoxicity study by Alamar blue assay 32
3-2.3. LINCS drug screening 34
4. Discussion 36
5. Reference 38
6. Supplement 41
7. Appendix 43
參考文獻 1.Li DJ. [Integration of traditional Chinese and Western medicine]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001;21(2):140-1.
2.Miller LH, Su X. Artemisinin: discovery from the Chinese herbal garden. Cell. 2011;146(6):855-8.
3.Li WW, Guo H, Li HH, Wang LL, Fu H, Wang XM. Integration of traditional Chinese medicines and Western medicines for treating diabetes mellitus with coronary heart disease: a systematic review. J Altern Complement Med. 2013;19(6):492-500.
4.Ximin. Z, Jipeng. Z, Zheng. W. Analysis on Chinese Herbs Properties of Anti Lung and Colorectal Cancer CHINESE MEDICINE MODERN DISTANCE EDUCATION OF CHINA. 2009:76-7.
5.Zhu YJ, Zhang HB, Liu LR, Liu YH, Zhang FL, Bai JP, et al. Yin-Cold or Yang-Heat Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept. Evid Based Complement Alternat Med. 2017;2017:7063859.
6.Wong WC, Lee A, Wong SY, Wu SC, Robinson N. Strengths, weaknesses, and development of Traditional Chinese Medicine in the health system of Hong Kong: through the eyes of future Western doctors. J Altern Complement Med. 2006;12(2):185-9; discussion 91-2.
7.Wu J, Xie J, Zhang QL, Lin ZX, Xie H, Sun B. [Research progress on meridian-guiding theory of traditional Chinese medicine]. Zhongguo Zhong Yao Za Zhi. 2016;41(13):2428-34.
8.Shifeng. Overview of Research on Traditional Chinese Medicinine Channel Tropism. Journal Of Liaoning University of TCM. 2014(03- 0127- 04):03-4.
9.Gu H, Zhang YL, Wang Y, Qiao YJ. [Study on characteristics of pharmacological effects of traditional Chinese medicines distributing along lung meridian based on medicinal property combination]. Zhongguo Zhong Yao Za Zhi. 2014;39(13):2400-3.
10.Ma H, Horiuchi KY. Chemical microarray: a new tool for drug screening and discovery. Drug Discov Today. 2006;11(13-14):661-8.
11. Feferman T, Aricha R, Menon R, Souroujon MC, Berrih-Aknin S, Fuchs S. DNA microarray in search of new drug targets for myasthenia gravis. Ann N Y Acad Sci. 2007;1107:111-7.
12.Duan Q, Reid SP, Clark NR, Wang Z, Fernandez NF, Rouillard AD, et al. L1000CDS(2): LINCS L1000 characteristic direction signatures search engine. NPJ Syst Biol Appl. 2016;2.
13.Wang Z, Clark NR, Ma′ayan A. Drug-induced adverse events prediction with the LINCS L1000 data. Bioinformatics. 2016;32(15):2338-45.
14.Duan Q, Flynn C, Niepel M, Hafner M, Muhlich JL, Fernandez NF, et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 2014;42(Web Server issue):W449-60.
15.Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171(6):1437-52 e17.
16.Liu C, Su J, Yang F, Wei K, Ma J, Zhou X. Compound signature detection on LINCS L1000 big data.(2) Mol Biosyst. 2015;11(3):714-22.
17.Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171(6):1437-52 e17.
18.Liu J, Wang S, Zhang Y, Fan HT, Lin HS. Traditional Chinese medicine and cancer: History, present situation, and development. Thorac Cancer. 2015;6(5):561-9.
19. Liu JX, Shi ZM, Xu ZY. Studies on late primary adenocarcinoma of lung treated by methods of nourishing yin to replenish fluid and warming Yang to benefit Qi. J Tradit Chin Med. 1995;36:155–158.
20. Xu ZY, Jin CJ, Zhou CC, et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol. 2011;137:1117–1122.
21. Zhang DZ, Xu JD. Clinical and experimental researches on improving radiation sensibility for lung cancer patients. Chin J Surg Integr Tradit West Med. 1998;4:71–75. (In Chinese.)
22. Zhou DH, Lin LZ, Zhou YQ. Effect of Chinese herbal medicine in prolonging median survival time in patients with non-small-cell lung cancer. J Guangzhou Univ Tradit Chin Med. 2005;7:255–258.
指導教授 蘇立仁(Li-Jen Su) 審核日期 2018-8-17
推文 facebook   plurk   twitter   funp   google   live   udn   HD   myshare   reddit   netvibes   friend   youpush   delicious   baidu   
網路書籤 Google bookmarks   del.icio.us   hemidemi   myshare   

若有論文相關問題,請聯絡國立中央大學圖書館推廣服務組 TEL:(03)422-7151轉57407,或E-mail聯絡  - 隱私權政策聲明